A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population

Launched by ASTRAZENECA · May 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying asthma in a group of people from China. The researchers want to learn more about the different types of asthma and how it affects patients. They will look at patient characteristics, treatment methods, and biological markers (which are signs in the body that can help understand the disease) to find out why some people have better or worse outcomes. This information could help create more personalized treatments for asthma in the future.

To participate in this study, individuals must be between 18 to 75 years old and have been diagnosed with asthma for at least three months. They should also meet certain health criteria. Participants can expect to undergo assessments and provide information about their health and treatment experiences. It's important to know that people with recent drug or alcohol abuse, pregnant women, and those with certain health conditions won't be eligible to join. The trial is currently looking for participants, aiming to improve asthma care for the Chinese population.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 to 75 years of age
• • acceptable FEV1 (according to ATS and ERS)
• • compliance with study procedures All Asthma Cohorts
• • physician diagnosed Asthma greater or equal to 3 months prior to screening visit
• Exclusion Criteria:
• • history of alcohol or drug abuse within the past year
• • pregnant at time of an assessment
• • has an altered mental status at the time of informed consent
• • receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer
• • history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments
• • terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation
• • Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.